Acasti Pharma Price to Sales Ratio 2014-2023 | ACST
Historical PS ratio values for Acasti Pharma (ACST) over the last 10 years. The current P/S ratio for Acasti Pharma as of April 26, 2024 is .
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Acasti Pharma P/S Ratio Historical Data |
| Date |
Stock Price |
TTM Sales per Share |
Price to Sales Ratio |
| 2024-04-29 |
2.68 |
|
inf |
| 2023-12-31 |
2.89 |
0 |
0.00 |
| 2023-09-30 |
2.78 |
0 |
0.00 |
| 2023-06-30 |
3.15 |
0 |
0.00 |
| 2023-03-31 |
2.76 |
0 |
0.00 |
| 2022-12-31 |
3.01 |
0 |
0.00 |
| 2022-09-30 |
3.50 |
0 |
0.00 |
| 2022-06-30 |
5.15 |
0 |
0.00 |
| 2022-03-31 |
7.32 |
0 |
0.00 |
| 2021-12-31 |
7.56 |
$0.05 |
162.49 |
| 2021-09-30 |
12.00 |
$0.09 |
140.69 |
| 2021-06-30 |
26.95 |
$0.09 |
316.00 |
| 2021-03-31 |
28.80 |
$0.09 |
337.66 |
| 2020-12-31 |
15.60 |
$0.04 |
402.40 |
| 2020-09-30 |
9.61 |
0 |
0.00 |
| 2020-06-30 |
22.52 |
0 |
0.00 |
| 2020-03-31 |
18.22 |
0 |
0.00 |
| 2019-12-31 |
117.60 |
0 |
0.00 |
| 2019-09-30 |
90.72 |
0 |
0.00 |
| 2019-06-30 |
54.72 |
0 |
0.00 |
| 2019-03-31 |
48.96 |
0 |
0.00 |
| 2018-12-31 |
39.93 |
0 |
0.00 |
| 2018-09-30 |
61.92 |
0 |
0.00 |
| 2018-06-30 |
27.36 |
0 |
0.00 |
| 2018-03-31 |
48.96 |
0 |
0.00 |
| 2017-12-31 |
45.25 |
0 |
0.00 |
| 2017-09-30 |
68.16 |
$0.00 |
0.00 |
| 2017-06-30 |
63.36 |
$0.02 |
3822.15 |
| 2017-02-28 |
60.00 |
$0.03 |
2269.83 |
| 2016-11-30 |
67.20 |
$0.04 |
1849.47 |
| 2016-08-31 |
63.84 |
$0.03 |
1976.32 |
| 2016-05-31 |
72.00 |
$0.04 |
1906.81 |
| 2016-03-31 |
72.96 |
$0.03 |
2383.90 |
| 2016-02-29 |
72.00 |
$0.04 |
1858.61 |
| 2015-12-31 |
122.40 |
$0.64 |
192.23 |
| 2015-09-30 |
129.07 |
$0.73 |
177.72 |
| 2015-06-30 |
151.20 |
$0.76 |
200.22 |
| 2015-03-31 |
230.16 |
$0.99 |
232.79 |
| 2014-12-31 |
240.00 |
$1.29 |
185.75 |
| 2014-09-30 |
369.60 |
$1.34 |
276.06 |
| 2014-06-30 |
489.60 |
$2.91 |
168.22 |
| 2014-03-31 |
551.66 |
$2.70 |
204.45 |
| 2013-12-31 |
600.00 |
$1.80 |
333.91 |
| 2013-09-30 |
1137.60 |
$1.64 |
692.57 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.027B |
$0.000B |
|
Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R) is a medical food and currently Acasti's only commercialized product. Acasti Pharma Inc. is headquartered in Laval, Canada.
|
